Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Serum vitamin D3 levels and overall survival (OS) in patients (pts) with advanced biliary tract cancer (BTC): Analysis of the NIFTY trial cohort.
Authors
So Heun Lee
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea;
So Heun Lee , Jaekyung Cheon , Ilhwan Kim , Kyu-Pyo Kim , Baek-Yeol Ryoo , Jae Ho Jeong , Myoung Joo Kang , Byung Woog Kang , Hyewon Ryu , Ji Sung Lee , Changhoon Yoo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Other
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 613)
DOI
10.1200/JCO.2023.41.4_suppl.613
Abstract #
613
Poster Bd #
G6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter phase Ib/II study of liposomal-irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) with nivolumab as second-line therapy for patients with advanced biliary tract cancer (BilT-03).
First Author: Vaibhav Sahai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).
First Author: Mairead Geraldine McNamara
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Significance of alterations in DNA damage repair (DDR) genes in advanced biliary cancers (ABCs) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multicentre, open-label ABC-06 trial.
First Author: Angela Lamarca
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.
First Author: Darren Cowzer